📈 Economy · Tomorrow

AstraZeneca PLC (LON: AZN; NASDAQ: AZN) beats analyst Core EPS consensus of approx. USD 4.80 per ADS for H1 2026 (29 July 2026, before market open) and confirms full-year guidance (confirmed by AstraZeneca press release)

Hit ✦ AI-generated prediction Published on 26. July 2026 · Predicted for 29. July 2026 · Based on: Statistical Pattern

Probability

68%

AstraZeneca has consistently beaten consensus expectations over the past six semi-annual and quarterly results, driven by oncology blockbusters (Tagrisso, Enhertu, Imfinzi) and the rare disease portfolio (Ultomiris, Soliris). FY2026 Core EPS growth of ≥10% YoY is company guidance. H1 2026 boosted by Farxiga launches in new indications and emerging market growth. No direct Polymarket data; historical beat probability >70% for AZ. Risks: FX pressure USD/GBP, generic competition for Tagrisso.

Data basis for this prediction

AstraZeneca IR: FY2025 Full Year Results – Core EPS Wachstumspfad, Guidance FY2026, Februar 2026
Reuters: AstraZeneca H1 2026 Earnings Preview – Oncology pipeline momentum, Juli 2026
Yahoo Finance: AZN Earnings History 2024–2026 – Konsekutive Beats, Stand Juli 2026
Macrotrends: AstraZeneca Core EPS Quarterly History 2023–2026

Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.

Verdict: Hit

AstraZeneca veröffentlichte die H1/Q2-2026-Ergebnisse am 27. Juli 2026 (2 Tage früher als die vorhergesagten 29. Juli 2026). Der Core-EPS für H1 2026 betrug $5,21 (+12 % YoY) und übertraf den prognostizierten Konsens von ~$4,80 deutlich (~+8,5 %). Für Q2 allein lag der Core-EPS bei $2,63 gegenüber einem Konsens von $2,48 (Beat von +$0,15 bzw. +6 %). Die Jahresprognose wurde vollständig bestätigt: Umsatzwachstum im mittleren bis oberen einstelligen Bereich und Core-EPS-Wachstum im niedrigen zweistelligen Bereich (CER). Treiber waren wie erwartet Onkologie (+15 % Umsatz) und Rare Disease. Quellen: AstraZeneca Pressemitteilung (astrazeneca.com, 27.07.2026); Nasdaq Press Release (nasdaq.com/press-release/astrazeneca-results-h1-and-q2-2026-2026-07-27); Investing.com Earnings Call Transcript; BiotechReality.com H1 2026 Analyse.

Related Predictions

📈 Economy ✦ AI

S&P 500 (SPX) closes above 7,500 on Friday, 13 November 2026 (confirmed via NYSE closing price or Bloomberg by 14 November 2026, 10:00 ET)

The S&P 500 dropped 4.36% on 5 November 2026 to 7,353.73 — its steepest one-day fall since April 2025 — triggered by an AI-chip selloff that wiped out the post-midterm rally (4 November: +1.72% to 7,698.80). Closing above 7,500 by 13 November requires a +2.0% recovery over 6 trading sessions. Goldman Sachs, Morgan Stanley and JPMorgan maintain year-end targets of 7,400–8,100; S&P 500 EPS growth consensus for 2026 stands at +14% YoY. Downside risks: elevated Treasury yields, persistent AI capex uncertainty. No specific Polymarket/Kalshi market found for this level.

62%

Next Week · Predicted for 13. Nov 2026

📈 Economy ✦ AI

US Consumer Price Index (headline CPI) for October 2026 exceeds 3.7 percent year-on-year — BLS release November 10, 2026, 8:30 AM ET (confirmed by BLS or Bloomberg by November 10, 2026, 10:00 AM ET)

The BLS releases October 2026 CPI on November 10, 2026 at 8:30 AM ET. Nowflation forecasts 3.82 percent YoY; the Cleveland Fed nowcasting model forecasts 3.74 percent — both clearly above the 3.7 percent threshold. The September 2026 prior reading was exactly 3.7 percent. Rising energy prices (Strait of Hormuz effectively closed since mid-October) and stable core inflation support a further uptick. An existing open platform prediction covers CPI >3.5%; this forecast raises the bar by 20 basis points. A miss would primarily require unexpected weakness in the energy component or food prices.

65%

Next Week · Predicted for 10. Nov 2026

📈 Economy ✦ AI

Gold (XAU/USD Spot) closes above $4,400 per ounce on 31 December 2026 (confirmed by Bloomberg or Kitco by 1 January 2027)

Gold (XAU/USD) rose to $4,134.83 on 5 November 2026 — driven by the Democratic midterm sweep (higher fiscal spending expected) and persistent inflation pressure. Kalshi's Dec 31 settlement market shows ~32% probability for a close above $4,400 and ~43% for above $4,300. Reaching the $4,400 year-end target would require a further ~6.4% gain. Supporting factors: fiscal expansion, geopolitical risks, structurally high central bank demand; UBS forecasts $4,800, JPMorgan $6,000 at year-end. Headwind: hawkish Fed stance (Polymarket: 72.5% for a December rate hike to 4.00–4.25%). Prediction anchors on Kalshi's ~32% for >$4,400.

32%

Next Year · Predicted for 31. Dec 2026